NEWS

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss the company’s R&D strategy and capabilities while providing insights into its pipeline and long-term growth plans.

The company’s leadership team discussed its differentiated research platforms and R&D framework, which are intended to drive productivity, deliver high quality early-stage candidates and accelerate the company’s R&D timelines. The company shared plans for six new registrational assets, which according to its press release, include: “CD19-directed NEX T cell therapy BMS986353, expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus. 

Potential first cell therapy targeting GPRC5D, our CAR T BMS-986393, starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). BCMA x CD3 T-cell engager, alnuctumab, advancing into a phase 3 trial for RRMM. Potential first-in-class protein degrader, golcadomide, progressing into a phase 3 trial in first-line large B-cell lymphoma. The first asset from BMS’ novel ligand-directed protein degradation platform, androgen receptor degrader, moving into pivotal studies in metastatic castration-resistant prostate cancer. Potential best-in-class BET inhibitor, BMS-986158, for myelofibrosis expecting proof-of-concept data.”

Chris Boerner PhD, executive vice president and chief operating officer at BMS, added: “Science and innovation derived from R&D are critical to the continued success of our company and represent the core of BMS’ vision to transform patients’ lives. We are further enhancing our R&D engine to strengthen scientific leadership, accelerate our promising pipeline and drive increased productivity. This work is a key enabler of our goal of delivering long-term sustainable growth and ensuring we help more patients prevail over serious diseases.”